Panacea Biotec per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
−₹1.16−₹0.88−₹1.37−₹0.19−₹5.51
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−₹1.16−₹0.88−₹1.37−₹0.19−₹5.51
₹136.19₹136.19₹136.18₹137.37₹137.62
₹109.73₹104.37₹91.21₹91.22₹75.03
—₹2.72−₹4.46−₹0.02−₹69.08
−₹6.10−₹6.10−₹12.67−₹12.69−₹75.76
6.16.16.16.16.1
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

PANACEABIO₹329.05

Panacea Biotec Limited

· Pharma & Health
₹ CrorePeersSAIPARENTHIKALINDOCODCALWINDLASHESTERBIOSOLARASYNCOMFMcap ₹2,017 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS-5.51-0.19-1.37-0.88-1.16
Diluted EPS-5.51-0.19-1.37-0.88-1.16
Book Value per Share137.62137.37136.18136.19136.19
Revenue per Share75.0391.2291.21104.37109.73
Cash Flow per Share-69.08-0.02-4.462.72—
Free Cash Flow per Share-75.76-12.69-12.67-6.10-6.10
Shares Outstanding (cr)6.16.16.16.16.1
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.